Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice

BACKGROUND: Dapagliflozin, a sodium glucose transporter protein-2 (SGLT-2) inhibitor, reduces the risk for cardiovascular diseases. However, the influence of dapagliflozin on nondissecting abdominal aortic aneurysms (AAAs) remains unclear. METHODS: AAAs were created in male C57BL/6 mice via intra-ao...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haole, Wei, Panpan, Fu, Weilai, Xia, Congcong, Li, Yankui, Tian, Kangli, Li, Yafeng, Cheng, Daxin, Sun, Jiaying, Xu, Yangwei, Lu, Ming, Xu, Boyu, Zhang, Yali, Wang, Rong, Wang, Weirong, Xu, Baohui, Liu, Enqi, Zhao, Sihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816542/
https://www.ncbi.nlm.nih.gov/pubmed/35126822
http://dx.doi.org/10.1155/2022/8502059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816542/
https://www.ncbi.nlm.nih.gov/pubmed/35126822
http://dx.doi.org/10.1155/2022/8502059

Ejemplares similares